Earnings boost drives gains: Concentrix shares climbed nearly 9.4 percent to close at $32.94 after investors reacted positively to an earnings beat. Market participants noted the move followed a period of oversold conditions that had weighed on the stock. The session stood out amid broader global uncertainties that tempered enthusiasm elsewhere.
Compensation shift sparks chatter: Recent adjustments to the company's change-of-control compensation plan drew attention from observers tracking potential strategic developments. Improved institutional holdings, including from major players like Fidelity, were highlighted as a constructive signal. Discussion centered on how these elements might influence future positioning without speculating on valuation levels.
Note: This discussion summary was generated from an AI condensation of post data.
Concentrix Insider Trading Activity
Concentrix insiders have traded $CNXC stock on the open market 4 times in the past 6 months. Of those trades, 3 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $CNXC stock by insiders over the last 6 months:
- BRUXELLES LAMBERT GROUPE sold 6,000,000 shares for an estimated $133,500,000
- ANDRE S VALENTINE (Chief Financial Officer) purchased 2,500 shares for an estimated $69,869
- CHRISTOPHER A CALDWELL (President and CEO) has made 2 purchases buying 2,000 shares for an estimated $48,219 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Concentrix Revenue
Concentrix had revenues of $2.5B in Q2 2026. This is an increase of 1.87% from the same period in the prior year.
You can track CNXC financials on Quiver Quantitative's CNXC stock page.
You can access data on CNXC stock through the Quiver Quantitative API.
Concentrix Hedge Fund Activity
We have seen 147 institutional investors add shares of Concentrix stock to their portfolio, and 230 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GROUPE BRUXELLES LAMBERT removed 6,000,000 shares (-68.4%) from their portfolio in Q2 2026, for an estimated $134,430,000
- BLACKROCK, INC. added 2,616,644 shares (+64.4%) to their portfolio in Q2 2026, for an estimated $58,625,908
- AQR CAPITAL MANAGEMENT LLC removed 1,559,784 shares (-32.3%) from their portfolio in Q2 2026, for an estimated $34,946,960
- KOPERNIK GLOBAL INVESTORS, LLC added 1,548,460 shares (+95.2%) to their portfolio in Q2 2026, for an estimated $34,693,246
- FMR LLC added 1,489,652 shares (+35.3%) to their portfolio in Q2 2026, for an estimated $33,375,653
- CITADEL ADVISORS LLC removed 1,226,979 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $27,490,464
- UBS GROUP AG added 879,754 shares (+38.5%) to their portfolio in Q2 2026, for an estimated $19,710,888
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Concentrix Analyst Ratings
Wall Street analysts have issued reports on $CNXC in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Baird issued a "Outperform" rating on 06/30/2026
To track analyst ratings and price targets for Concentrix, check out Quiver Quantitative's $CNXC forecast page.
Concentrix Price Targets
Multiple analysts have issued price targets for $CNXC recently. We have seen 4 analysts offer price targets for $CNXC in the last 6 months, with a median target of $30.0.
Here are some recent targets:
- David Koning from Baird set a target price of $30.0 on 06/30/2026
- Luke Morison from Canaccord Genuity set a target price of $45.0 on 06/30/2026
- Vincent Colicchio from Barrington Research set a target price of $30.0 on 06/30/2026
- Ruplu Bhattacharya from B of A Securities set a target price of $26.0 on 06/30/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
